Forth raises £1.6m from Trajan Scientific and Medical and the Development Bank of Wales to launch female health products.
The funding round includes backing from strategic and regional investors to support the rollout of Female Hormone Mapping.
Forth provides biochemistry tracking and health insights with a focus on female hormonal health.
Forth has secured £1.6m in funding to launch a new female health product and expand its biomarker tracking offerings. The investment round included participation from Trajan Scientific and Medical alongside the Development Bank of Wales, which contributed £250k in follow-on equity. The capital will enable the company to introduce its Female Hormone Mapping service and scale its operations in the preventative health market.
From the founder
"Today, more and more people are realising that understanding and measuring your body’s biochemistry is key for a long and healthy life. For women in particular, gaining unique insight into how their hormone levels fluctuate throughout their unique cycle can give women the support they have been lacking and help to close the gender health gap"
Sarah Bolt
CEO and Co-founder at Forth
Investor perspective
"We have known the founders and majority shareholders at Forth for some time. We share common values around delivering good science that helps people achieve better health outcomes. We are both intensely focused on delivering impact and working together we believe we will do just that."
Stephen Tomisich
Chief Executive Officer and Managing Director, Trajan Scientific and Medical
Use of funds
- 01Continue product development
